Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03678883 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

9-ING-41 in Patients With Advanced Cancers

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 3, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 2025 to Jun 2026
    • Study completion date: Jan 2026 to Jun 2026
    • Publications: details revised at 13 of 16 entries
    v50
  2. Publications: details revised at 13 of 16 entriesv49
  3. Primary completion date: Nov 2024 to Jan 2025
    • Study completion date: Nov 2025 to Jan 2026
    v48
  4. Re-verified, no change to tracked fieldsv47
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 66 of 66 sites
    v46
Show 44 earlier versionsHide 44 earlier versions
  1. Site contacts updated at 2 of 66 sitesv45
  2. Site contacts updated at 1 of 66 sitesv44
  3. Study sites: 63 to 66v43
  4. Study sites: 52 to 63v42
  5. Study sites: 45 to 52v41
  6. Study sites: 37 to 45v40
  7. Study sites: 34 to 37v39
  8. Study sites: 31 to 34v38
  9. Site contacts updated at 1 of 31 sitesv37
  10. Study sites: 26 to 31v36
  11. Re-verified, no change to tracked fieldsv35
  12. Study sites: 24 to 26v34
  13. Site details revised at 2 of 24 sitesv33
  14. Study sites: 17 to 24v32
  15. Phase: Phase 1/2 to Phase 2v31 Show 5 more changesShow less
    • Primary completion date: Nov 2022 to Nov 2024
    • Primary endpoints: 1 to 2
    • Study sites: 13 to 17
    • Study completion date: Nov 2023 to Nov 2025
    • Eligibility criteria expanded, about 770 words
  16. Site details revised at 1 of 13 sitesv30
  17. Collaborators shortened, about 3 wordsv29
  18. Study sites: 15 to 13
    • Study description shortened, about 68 words
    v28
  19. Study completion date: Nov 2022 to Nov 2023
    • Study description shortened, about 11 words
    v27
  20. Site details revised at 1 of 15 sitesv26
  21. Study sites: 13 to 15v25
  22. Re-verified, no change to tracked fieldsv24
  23. Site details revised at 2 of 13 sitesv23
  24. Re-verified, no change to tracked fieldsv22
  25. Study description shortened, about 46 words
    • Site details revised at 4 of 13 sites
    v21
  26. Re-verified, no change to tracked fieldsv20
  27. Study sites: 12 to 13v19
  28. Study sites: 11 to 12v18
  29. Study sites: 8 to 11
    • Eligibility criteria shortened, about 31 words
    v17
  30. Study sites revised (8)v16
  31. Study sites: 7 to 8v15
  32. Publications: 15 to 16v14
  33. Publications: 14 to 15v13
  34. Publications: 13 to 14v12
  35. Study sites: 6 to 7v11
  36. Enrollment target: 250 to 350v10 Show 6 more changesShow less
    • Study sites: 5 to 6
    • Interventions: 9-ING-41 (Drug), Carboplatin. (Drug), Doxorubicin. (Drug), Gemcitabine - 21 day cycle (Drug), Gemcitabine - 28 day cycle (Drug), Lomustine… to 9-ING-41 (Drug), Carboplatin. (Drug), Doxorubicin. (Drug), Gemcitabine - 21 day cycle (Drug), Gemcitabine - 28 day cycle (Drug), Irinotecan…
    • Eligibility criteria shortened, about 130 words
    • Publications: 12 to 13
    • Study arms: 7 to 8
    • Study description expanded, about 1 word
  37. Publications: 11 to 12v9
  38. Study sites: 4 to 5
    • Publications: 10 to 11
    v8
  39. Study sites: 3 to 4v7
  40. Study sites: 2 to 3
    • Start date changed from estimate of Dec 2018 to Jan 4, 2019
    v6
  41. Study sites: 1 to 2v5
  42. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Nov 2018 to Dec 2018
    • Publications: 9 to 10
    v4
  43. Primary endpoint revised
    • Study description expanded, about 102 words
    v3
  44. Study description expanded, about 285 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Actuate Therapeutics Inc.
2 trials monitored
See all monitored trials
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 6 more diseases
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Trial Details
NCT Number NCT03678883
Lead Sponsor Actuate Therapeutics Inc.
Conditions
(from sponsor)		 Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma +17 more
Related terms Bone Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Glioma, Hereditary Sensory and Autonomic Neuropathies, Kidney Neoplasms, Leukemia-Lymphoma, Adult T-Cell, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Sarcoma
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov